Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:MGTA

Magenta Therapeutics (MGTA) Stock Price, News & Analysis

Magenta Therapeutics logo

About Magenta Therapeutics Stock (NASDAQ:MGTA)

Advanced Chart

Key Stats

Today's Range
$0.68
$0.76
50-Day Range
$0.36
$0.76
52-Week Range
$0.32
$2.07
Volume
376,000 shs
Average Volume
848,835 shs
Market Capitalization
$42.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive MGTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Magenta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MGTA Stock News Headlines

The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.
See More Headlines

MGTA Stock Analysis - Frequently Asked Questions

Magenta Therapeutics, Inc. (NASDAQ:MGTA) announced its quarterly earnings results on Thursday, November, 4th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.02.

Magenta Therapeutics shares split on the morning of Thursday, September 7th 2023.The 2-1 split was announced on Thursday, September 7th 2023. The newly minted shares were payable to shareholders after the market closes on Thursday, September 7th 2023. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

Magenta Therapeutics (MGTA) raised $100 million in an IPO on Thursday, June 21st 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Magenta Therapeutics investors own include TherapeuticsMD (TXMD), Sorrento Therapeutics (SRNE), NIO (NIO), Oncobiologics (OTLK), VBI Vaccines (VBIV), Corbus Pharmaceuticals (CRBP) and Dynavax Technologies (DVAX).

Company Calendar

Last Earnings
11/04/2021
Today
7/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:MGTA
Fax
N/A
Employees
67
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$76.46 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$1.23 per share
Price / Book
0.57

Miscellaneous

Free Float
51,456,000
Market Cap
$42.44 million
Optionable
Not Optionable
Beta
2.12
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

This page (NASDAQ:MGTA) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners